Protagenic Therapeutics (NASDAQ:PTIX) — Stock Price
Protagenic Therapeutics (NASDAQ:PTIX) is currently trading at $0.35 USD, up 12.90% today. Over the past 52 weeks, shares have ranged between $0.13 and $4.51. This page tracks Protagenic Therapeutics's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Protagenic Therapeutics stock valuation.
Protagenic Therapeutics (PTIX) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Protagenic Therapeutics's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Protagenic Therapeutics Income Statement — Revenue, Profit & Earnings by Year
Protagenic Therapeutics's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $50.29K | $28.22K | $30.00 | — | $286.00 |
| Gross Profit | $-50.29K | $-28.22K | $-30.00 | — | $-286.00 |
| Research & Development | $3.85 Million | $3.32 Million | $1.59 Million | $1.14 Million | $699.80K |
| SG&A | $1.76 Million | $1.21 Million | $1.97 Million | $3.00 Million | $1.85 Million |
| Total Operating Expenses | $5.70 Million | $4.50 Million | $3.56 Million | $4.14 Million | $2.55 Million |
| Operating Income | $-5.70 Million | $-4.53 Million | $-3.56 Million | $-4.14 Million | $-2.55 Million |
| EBITDA | $-5.47 Million | $-4.50 Million | $-3.42 Million | $-4.14 Million | $-2.55 Million |
| EBIT | $-5.53 Million | $-4.53 Million | $-3.42 Million | $-4.14 Million | $-2.55 Million |
| Interest Expense | $0.00 | $107.68K | $137.46K | $496.91K | $246.18K |
| Income Before Tax | $-5.53 Million | $-5.00 Million | $-3.56 Million | $-4.52 Million | $-2.55 Million |
| Income Tax Expense | — | $2.00 | $46.05K | $463.70K | $246.18K |
| Net Income | $-5.53 Million | $-5.00 Million | $-3.56 Million | $-4.52 Million | $-2.55 Million |
Protagenic Therapeutics Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Protagenic Therapeutics's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $2.13 Million | $1.96 Million | $4.32 Million | $8.04 Million | $11.06 Million |
| Total Current Assets | $2.30 Million | $1.88 Million | $4.20 Million | $8.04 Million | $11.06 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | $0.00 | $2.77 Million | $7.76 Million | $9.83 Million |
| Net Receivables | $41.52K | — | — | — | — |
| Inventory | $1.07K | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $6.82 Million | $942.76K | $655.25K | $1.12 Million | $1.12 Million |
| Total Current Liabilities | $6.82 Million | $942.76K | $655.25K | $1.12 Million | $799.53K |
| Long-term Debt | — | — | — | — | $318.43K |
| Net Debt | $943.26K | $-1.84 Million | $-1.29 Million | $129.04K | $-222.74K |
| Total Stockholder Equity | $-2.39 Million | $1.01 Million | $3.67 Million | $6.92 Million | $9.94 Million |
| Retained Earnings | $-9.11 Million | $-36.30 Million | $-30.78 Million | $-25.78 Million | $-22.22 Million |
Protagenic Therapeutics Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Protagenic Therapeutics generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-4.14 Million | $-4.22 Million | $-3.70 Million | $-1.99 Million | $-2.80 Million |
| Capital Expenditures | $3.00 | $0.00 | $149.78K | $1.80K | $4.00 |
| Free Cash Flow | $-4.14 Million | $-4.22 Million | $-3.85 Million | $-2.00 Million | $-2.80 Million |
| Investing Cash Flow | $943.18K | $2.80 Million | $4.78 Million | $1.60 Million | $-9.91 Million |
| Financing Cash Flow | $4.51 Million | $1.96 Million | $0.00 | $0.00 | $12.58 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | $562.95K | $923.14K | $666.83K | $864.68K | $1.52 Million |
| Depreciation | $255.92K | $50.29K | $28.22K | $30.00 | $427.14K |
| Change in Cash | $4.46 Million | $550.58K | $1.07 Million | $-325.98K | $-129.92K |
Protagenic Therapeutics Earnings History — EPS Actual vs. Analyst Estimates
Track Protagenic Therapeutics's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Nov 26, 2025 | -0.47 | — | — |
| Aug 29, 2025 | -1.37 | — | — |
| May 13, 2025 | -2.75 | — | — |
| Mar 31, 2025 | -0.24 | — | — |
| Nov 12, 2024 | -0.14 | — | — |
| Aug 14, 2024 | -0.36 | — | — |
| May 15, 2024 | -0.38 | — | — |
| Nov 14, 2023 | -0.32 | — | — |